title: Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma.
abstract: BRAF V600E is the most common somatic mutation seen in patients with metastatic melanoma. BRAF inhibitors (BRAFi), along with MEK inhibitors (MEKi), have been shown to improve overall survival in these patients with a median time to resistance of 6-10 months. We describe a patient with an ongoing response of 48 months on intermittent BRAFi therapy. She was started on vemurafenib at initial diagnosis, which was discontinued after a total of 39 weeks of therapy, and achieved a complete response due to cumulative toxicity. Upon evidence of progression on serial imaging following 81 weeks of disease-free status, BRAFi was resumed with dabrafenib, along with trametinib. Complete response was seen with seven weeks of treatment. Therapy was discontinued again, due to side effects, with an intention to pursue intermittent therapy. Serial imaging, so far, has shown no progression or recurrence of disease after over a year (66 weeks and ongoing) since discontinuation of therapy. This case underscores the clinical feasibility of intermittent BRAFi therapy in patients while still achieving a prolonged response. Disease control of 48 months, to date, has been achieved using therapy only "as needed" and keeping toxicities to the minimum.
authors.affiliation: Internal Medicine, Mayo Clinic, Scottsdale, AZ.
authors.forename: Tania
authors.initials: T
authors.lastname: Jain
authors.affiliation: Hematology Oncology, Mayo Clinic, Scottsdale, AZ.
authors.forename: Alan
authors.initials: A
authors.lastname: Bryce
keywords: braf inhibitor; melanoma
references.citation: Eur J Cancer. 2015 Jul;51(11):1435-43
references.pmid: 25980594
references.citation: Melanoma Res. 2012 Dec;22(6):466-72
references.pmid: 22584957
references.citation: Nature. 2013 Feb 14;494(7436):251-5
references.pmid: 23302800
references.citation: Ther Adv Med Oncol. 2014 Nov;6(6):262-6
references.pmid: 25364391
references.citation: N Engl J Med. 2011 Jun 30;364(26):2507-16
references.pmid: 21639808
references.citation: Nature. 2014 Apr 3;508(7494):118-22
references.pmid: 24670642
references.citation: N Engl J Med. 2012 Nov;367 (18):1694-703
references.pmid: 23020132
references.citation: Nature. 2010 Dec 16;468(7326):973-7
references.pmid: 21107323